These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 19331132)

  • 1. Distinct patient responses to activation of T-cells by free HER-2, G89 (777-789) and protected LRMK-linked HER-2, {AE-39 [p776 (Ava-774-788)], AE-47 [(Ava-776-788)] and AE-37[p776 (774-788)]} peptides could lead to development of personalized cancer vaccines.
    Li Y; Matsueda S; Efferson CL; Tsuda N; Kawano K; Gao H; Peoples GE; Ioannides CG
    Anticancer Res; 2009 Jan; 29(1):41-58. PubMed ID: 19331132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER-2 peptides p776 and F7, N-terminal-linked with Ii-Key tetramer (LRMK) help the proliferation of E75-TCR+ cells: The dependency of help on the side chains of LRMK-extended peptide pointed towards the T cell receptor.
    Li Y; Ishiyama S; Matsueda S; Tsuda N; Ioannides CG
    Oncol Rep; 2008 Jun; 19(6):1445-52. PubMed ID: 18497949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-terminally LRMK-linked HER-2 peptides, AE-37 [p776(774-788)] and AE-47 [Ava-F7(776-788)], aid differentiation of E75-TCR+CD8+ cells to perforin-positive cells.
    Matsueda S; Gao H; Efferson CL; Tsuda N; Ishiyama S; Li Y; Ioannides MG; Fisk B; Peoples GE; Ioannides CG
    Anticancer Res; 2009 Jul; 29(7):2427-35. PubMed ID: 19596910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulation of cells from a non-invaded and an invaded lymph node with a HER-2+ tumor with peptides corresponding to T-cell epitopes E75 and G89 induced expansion of central memory cells (TCM) from the metastasis-negative lymph nodes.
    Ko BK; Efferson CL; Kawano K; Kuerer HM; Sahin A; Murray JL; Ioannides CG
    Int J Oncol; 2004 Jun; 24(6):1413-8. PubMed ID: 15138582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Helper peptide G89 (HER-2:777-789) and G89-activated cells regulate the survival of effectors induced by the CTL epitope E75 (HER-2, 369-377). Correlation with the IFN-gamma: IL-10 balance.
    Lee TV; Johnston DA; Thomakos N; Honda T; Efferson CL; Ioannides CG
    Anticancer Res; 2002; 22(3):1481-90. PubMed ID: 12168827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients.
    Tuttle TM; Anderson BW; Thompson WE; Lee JE; Sahin A; Smith TL; Grabstein KH; Wharton JT; Ioannides CG; Murray JL
    Clin Cancer Res; 1998 Aug; 4(8):2015-24. PubMed ID: 9717833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen.
    Kobayashi H; Wood M; Song Y; Appella E; Celis E
    Cancer Res; 2000 Sep; 60(18):5228-36. PubMed ID: 11016652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
    Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
    Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer.
    Zamani P; Teymouri M; Nikpoor AR; Navashenaq JG; Gholizadeh Z; Darban SA; Jaafari MR
    Eur J Cancer; 2020 Apr; 129():80-96. PubMed ID: 32145473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced CD4+ T-cell response in DR4-transgenic mice to a hybrid peptide linking the Ii-Key segment of the invariant chain to the melanoma gp100(48-58) MHC class II epitope.
    Kallinteris NL; Wu S; Lu X; Humphreys RE; von Hofe E; Xu M
    J Immunother; 2005; 28(4):352-8. PubMed ID: 16000953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma.
    Tomimaru Y; Mishra S; Safran H; Charpentier KP; Martin W; De Groot AS; Gregory SH; Wands JR
    Vaccine; 2015 Mar; 33(10):1256-66. PubMed ID: 25629522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors.
    Sotiriadou NN; Kallinteris NL; Gritzapis AD; Voutsas IF; Papamichail M; von Hofe E; Humphreys RE; Pavlis T; Perez SA; Baxevanis CN
    Cancer Immunol Immunother; 2007 May; 56(5):601-13. PubMed ID: 16960693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion.
    Knutson KL; Disis ML
    Clin Exp Immunol; 2004 Feb; 135(2):322-9. PubMed ID: 14738463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo induction of a Th cell response toward peptides of the melanoma-associated glycoprotein 100 protein selected by the TEPITOPE program.
    Cochlovius B; Stassar M; Christ O; Raddrizzani L; Hammer J; Mytilineos I; Zöller M
    J Immunol; 2000 Oct; 165(8):4731-41. PubMed ID: 11035118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-gamma production in response to in vitro stimulation with collagen type II in rheumatoid arthritis is associated with HLA-DRB1(*)0401 and HLA-DQ8.
    Berg L; Rönnelid J; Sanjeevi CB; Lampa J; Klareskog L
    Arthritis Res; 2000; 2(1):75-84. PubMed ID: 11219392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity of undifferentiated, high-TCR density CD8+ cells to methylene groups appended to tumor antigen determines their differentiation or death.
    Kawano K; Efferson CL; Peoples GE; Carter D; Tsuda N; Murray JL; Ioannides CG
    Cancer Res; 2005 Apr; 65(7):2930-7. PubMed ID: 15805296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer.
    Gillogly ME; Kallinteris NL; Xu M; Gulfo JV; Humphreys RE; Murray JL
    Cancer Immunol Immunother; 2004 Jun; 53(6):490-6. PubMed ID: 14740174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients.
    Hueman MT; Dehqanzada ZA; Novak TE; Gurney JM; Woll MM; Ryan GB; Storrer CE; Fisher C; McLeod DG; Ioannides CG; Ponniah S; Peoples GE
    Clin Cancer Res; 2005 Oct; 11(20):7470-9. PubMed ID: 16243821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Th1 cell reactivity and HLA-DR binding prediction for promiscuous recognition of MPT63 (Rv1926c), a major secreted protein of Mycobacterium tuberculosis.
    Mustafa AS
    Scand J Immunol; 2009 Mar; 69(3):213-22. PubMed ID: 19281533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient.
    Knutson KL; Disis ML
    Hum Immunol; 2002 Jul; 63(7):547-57. PubMed ID: 12072190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.